Approved regulatory verdict
Evidence outlook
Approved: ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
Source for the program status
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Multiple Myeloma · investigational · Featured evidence · 3 investigational Featured evidence · 3
Competitive landscape 67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 23 further along in development.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Iberdomide: this drug Phase 3 Small molecule Cereblon E3 ubiquitin-ligase Lenalidomide Approved Small molecule Cereblon E3 ubiquitin-ligase , Thalidomide Analog Pomalidomide Approved Small molecule Cereblon E3 ubiquitin-ligase , Cereblon (CRBN) Thalidomide Approved Small molecule Cereblon E3 ubiquitin-ligase Mezigdomide Phase 3 Small molecule Cereblon E3 ubiquitin-ligase Cemsidomide Phase 2 Small molecule Cereblon E3 ubiquitin-ligase ICP-490 Phase 1/2 Small molecule Cereblon E3 ubiquitin-ligase TQB3820 Phase 1 Small molecule Cereblon E3 ubiquitin-ligase Belantamab Mafodotin Approved Antibody–drug conjugate BCMA Bortezomib Approved Small molecule Proteasome Carfilzomib Approved Small molecule Proteasome Ciltacabtagene Autoleucel Approved Cell therapy BCMA Daratumumab Approved Monoclonal antibody CD38 Denosumab Approved Monoclonal antibody RANKL Elotuzumab Approved Monoclonal antibody SLAMF7 (CS1/CD319) Elranatamab Approved Multispecific antibody BCMA x CD3
…and 52 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (30 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2) November 2026 (1) Phase 1 Multiple Myeloma Active not recruiting
Est. primary completion 2026-11 ·
NCT05560399 ·
CT.gov ↗ What to watch December 2026 (1) Phase 1 Multiple Myeloma Recruiting
Est. primary completion 2026-12-31 ·
NCT06465316 ·
CT.gov ↗ What to watch 2027 (9) April 2027 (2) Phase 3 Multiple Myeloma Recruiting
Est. primary completion 2027-04 ·
NCT05558319 ·
CT.gov ↗ What to watch Phase 2 Multiple Myeloma Active not recruiting
Est. primary completion 2027-04-26 ·
NCT05354557 ·
CT.gov ↗ What to watch July 2027 (2) Phase 1 Multiple Myeloma Not yet recruiting
Est. primary completion 2027-07 ·
NCT07727668 ·
CT.gov ↗ What to watch Phase 1 Multiple Myeloma Recruiting
Est. primary completion 2027-07-31 ·
NCT06348108 ·
CT.gov ↗ What to watch September 2027 (1) Phase 2 Smoldering Plasma Cell Myeloma Recruiting
Est. primary completion 2027-09-01 ·
NCT04776395 ·
CT.gov ↗ What to watch November 2027 (2) Phase 1 Multiple Myeloma Active not recruiting
Est. primary completion 2027-11-16 ·
NCT06215118 ·
CT.gov ↗ What to watch Phase 3 Multiple Myeloma Active not recruiting
Est. primary completion 2027-11-16 ·
NCT04975997 ·
CT.gov ↗ What to watch December 2027 (2) Phase 2 Multiple Myeloma Active not recruiting
Est. primary completion 2027-12 ·
NCT04392037 ·
CT.gov ↗ What to watch Phase 2 Multiple Myeloma Recruiting
Est. primary completion 2027-12-31 ·
NCT06107738 ·
CT.gov ↗ What to watch 2028 (6) March 2028 (1) Phase 2 Multiple Myeloma Recruiting
Est. primary completion 2028-03 ·
NCT05272826 ·
CT.gov ↗ What to watch July 2028 (1) Phase 1/2 Multiple Myeloma Recruiting
Est. primary completion 2028-07-31 ·
NCT05583617 ·
CT.gov ↗ What to watch August 2028 (2) Phase 1/2 Multiple Myeloma Active not recruiting
Est. primary completion 2028-08 ·
NCT05434689 ·
CT.gov ↗ What to watch Phase 1 Multiple Myeloma Recruiting
Est. primary completion 2028-08-01 ·
NCT06121843 ·
CT.gov ↗ What to watch December 2028 (2) Phase 3 Multiple Myeloma Active not recruiting
Est. primary completion 2028-12 ·
NCT06216158 ·
CT.gov ↗ What to watch Phase 1 Lymphoma, B-Cell Active not recruiting
Est. primary completion 2028-12-01 ·
NCT04884035 ·
CT.gov ↗ What to watch 2029 (7) March 2029 (2) Phase 2 Multiple Myeloma Recruiting
Est. primary completion 2029-03-01 ·
NCT05896228 ·
CT.gov ↗ What to watch Phase 3 Multiple Myeloma Active not recruiting
Est. primary completion 2029-03-15 ·
NCT05827016 ·
CT.gov ↗ What to watch July 2029 (1) Phase 1/2 Multiple Myeloma Not yet recruiting
Est. primary completion 2029-07-01 ·
NCT07601100 ·
CT.gov ↗ What to watch August 2029 (1) Phase 1 Non-Hodgkin Lymphoma Active not recruiting
Est. primary completion 2029-08-05 ·
NCT05169515 ·
CT.gov ↗ What to watch September 2029 (1) Phase 1/2 Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma Not yet recruiting
Est. primary completion 2029-09-30 ·
NCT07437963 ·
CT.gov ↗ What to watch December 2029 (2) Phase 2 Multiple Myeloma Active not recruiting
Est. primary completion 2029-12 ·
NCT05527340 ·
CT.gov ↗ What to watch Phase 1/2 Multiple Myeloma Recruiting
Est. primary completion 2029-12-31 ·
NCT06518551 ·
CT.gov ↗ What to watch 2030 (1) January 2030 (1) Phase 2 Multiple Myeloma Active not recruiting
Est. primary completion 2030-01-01 ·
NCT04998786 ·
CT.gov ↗ What to watch 2031 (1) April 2031 (1) Phase 1/2 Multiple Myeloma Recruiting
Est. primary completion 2031-04-01 ·
NCT06785415 ·
CT.gov ↗ What to watch 2032 (1) November 2032 (1) Phase 2 Smouldering Myeloma Recruiting
Est. primary completion 2032-11 ·
NCT06762769 ·
CT.gov ↗ What to watch 2033 (1) October 2033 (1) Phase 3 Multiple Myeloma Not yet recruiting
Est. primary completion 2033-10-01 ·
NCT07624513 ·
CT.gov ↗ What to watch 2035 (1) December 2035 (1) Phase 1/2 Multiple Myeloma Recruiting
Est. primary completion 2035-12 ·
NCT06892522 ·
CT.gov ↗ What to watch 2036 (1) March 2036 (1) Phase 1 Multiple Myeloma Recruiting
Est. primary completion 2036-03 ·
NCT06896916 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (53) Multiple Myeloma (35) Other / comorbidity (18)
Phase 3 (5) Phase 2 (15) Phase 1/2 (13) Phase 1 (20) Appears in other studies (1)